FDA Inspection of Novartis Lab Raises More Questions About Data Falsification

Drug GMP Report
A Form 483 issued following an FDA inspection of Novartis subsidiary AveXis’ control testing laboratory — currently the focus of a data manipulation investigation by the agency — is raising concerns about the firm’s own investigation and when it knew about the data discrepancies.

To View This Article:


Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $157.00